Dr. Kai Rogers, a resident in the Pathology physician-scientist training program (PSTP), has received an NIH/NINDS grant award through its R25/UE5 funding mechanism. The University of Iowa R25/UE5 program, entitled “Carver College of Medicine Clinical Neuroscientist Training Program (CNS-TP)” is led by Drs. George Richerson and Kumar Narayanan in the Department of Neurology. This program acknowledges the critical need for physicians to be involved in basic research on human brain disease and provides direct support toward this goal.

Stephanie van de Wall, Ph.D. was the lead author of the study. Co-authors include Scott Anthony, Lisa Hancox and Lecia Epping from the Harty lab, Vladimir P. Badovinac Ph.D., also from U. Iowa Pathology as well as Ryan Langlois (U. Minnesota) and Dietmar Zehn (Technical University of Munich). The work was supported by grants from the NIH to VPB and JTH.

Dr. Harty received a new 2 year grant from the NIH entitled “Brain T cell interactions in microbial experienced mice.” The award totals $404,300, the project started June 4, 2024 and concludes April 30, 2026.

Cancer researcher Steven Offer, PhD investigates the genetic factors that increase the risk of a toxic reaction to the cancer drug Fluorouracil (5-FU). 5-FU, used since the 1970s to treat many cancers including colorectal, stomach, breast and cervical cancer, can be toxic to certain patients. While many cancer drugs can be toxic, what sets 5-FU apart is that severe illness and death is largely preventable.

Dr. Marco Hefti received a five-year NIH R01 award entitled “A non-canonical role for tau in early human brain development” from the National Institute of Neurological Disorders and Stroke. The award totals $561,007 and the project starts May 1, 2024 and concludes February 28, 2029.

Rachel Fitzjerrells, a Bioinformatics and Computational Biology PhD student in the Mangalam Lab, won the prestigious Max Smith Oral Presentation Award at the 71st Iowa Section AADOCR on February 13th, 2024.

Researchers at the National Institutes of Health, led by Dr. Natalie Shaw, have found that a toxic protein made by the body called DUX4 may be the cause of two very different rare genetic disorders. For patients who have facioscapulohumeral muscular dystrophy (FSHD), or a rare facial malformation called arhinia, this research discovery may eventually lead to therapies that can help people with these rare diseases.

Dr. Dao-Fu Dai received a five-year NIH R01 award entitled ‘Metabolic Reprogramming and FGF21 Signaling in Kidney Health and Polycystic Kidney Diseases’ from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

Dr. Jonathan Davick, MD, Clinical Assistant Professor of Pathology, has been named to the Children’s Oncology Group Renal Tumors Committee with the role of central pathology reviewer for rapid assessment and confirmation of Wilms tumors and other rare pediatric renal tumors on a national basis. He is one of only four pathology reviewers appointed to this role in the United States.